Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 100 | 2024 | 21683 | 4.020 |
Why?
|
Medical Oncology | 38 | 2024 | 2265 | 3.980 |
Why?
|
Cancer Care Facilities | 10 | 2020 | 402 | 2.360 |
Why?
|
Breast Neoplasms | 76 | 2024 | 20822 | 2.340 |
Why?
|
Rwanda | 33 | 2023 | 703 | 1.820 |
Why?
|
Delivery of Health Care | 25 | 2022 | 5319 | 1.800 |
Why?
|
Quality Indicators, Health Care | 10 | 2021 | 1831 | 1.540 |
Why?
|
Health Services Accessibility | 16 | 2023 | 5137 | 1.370 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 54 | 2022 | 11524 | 1.310 |
Why?
|
Quality of Health Care | 16 | 2021 | 4371 | 1.240 |
Why?
|
Paclitaxel | 14 | 2021 | 1708 | 1.220 |
Why?
|
Developing Countries | 18 | 2021 | 2815 | 1.210 |
Why?
|
Lymph Node Excision | 7 | 2021 | 1261 | 1.170 |
Why?
|
Delivery of Health Care, Integrated | 7 | 2023 | 941 | 1.130 |
Why?
|
Sentinel Lymph Node Biopsy | 3 | 2021 | 709 | 1.060 |
Why?
|
Hodgkin Disease | 15 | 2020 | 1415 | 0.910 |
Why?
|
Electronic Health Records | 8 | 2023 | 4468 | 0.890 |
Why?
|
Humans | 310 | 2024 | 744343 | 0.820 |
Why?
|
Lymph Nodes | 8 | 2021 | 3474 | 0.800 |
Why?
|
Privacy | 1 | 2024 | 239 | 0.790 |
Why?
|
Mastectomy, Segmental | 8 | 2021 | 956 | 0.790 |
Why?
|
Colonic Neoplasms | 6 | 2021 | 2541 | 0.780 |
Why?
|
Capacity Building | 2 | 2021 | 248 | 0.760 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2020 | 949 | 0.750 |
Why?
|
Needs Assessment | 4 | 2020 | 1147 | 0.740 |
Why?
|
Antineoplastic Agents | 26 | 2022 | 13695 | 0.730 |
Why?
|
World Health Organization | 6 | 2023 | 1318 | 0.730 |
Why?
|
Physicians | 7 | 2023 | 4567 | 0.720 |
Why?
|
Organizations | 1 | 2021 | 170 | 0.710 |
Why?
|
Patient Care Planning | 3 | 2020 | 921 | 0.700 |
Why?
|
Survivors | 6 | 2024 | 2291 | 0.680 |
Why?
|
Pharmaceutical Services | 2 | 2020 | 140 | 0.680 |
Why?
|
Hospitals | 5 | 2021 | 3952 | 0.650 |
Why?
|
Gastrointestinal Neoplasms | 2 | 2024 | 990 | 0.650 |
Why?
|
Chemotherapy, Adjuvant | 19 | 2022 | 3479 | 0.640 |
Why?
|
Drugs, Essential | 4 | 2022 | 73 | 0.620 |
Why?
|
Hematologic Diseases | 3 | 2012 | 498 | 0.620 |
Why?
|
Doxorubicin | 16 | 2020 | 2234 | 0.600 |
Why?
|
Quality Assurance, Health Care | 4 | 2019 | 2212 | 0.570 |
Why?
|
Relief Work | 1 | 2018 | 137 | 0.570 |
Why?
|
Lung Neoplasms | 19 | 2023 | 13102 | 0.570 |
Why?
|
Early Detection of Cancer | 11 | 2023 | 3086 | 0.560 |
Why?
|
Pathology | 2 | 2017 | 272 | 0.560 |
Why?
|
Information Dissemination | 2 | 2023 | 1099 | 0.550 |
Why?
|
Professional Practice | 3 | 2015 | 326 | 0.540 |
Why?
|
Female | 173 | 2024 | 380194 | 0.540 |
Why?
|
Mediastinal Neoplasms | 5 | 2008 | 423 | 0.530 |
Why?
|
Policy Making | 2 | 2018 | 554 | 0.520 |
Why?
|
Uterine Cervical Neoplasms | 6 | 2023 | 2020 | 0.520 |
Why?
|
Rural Population | 7 | 2020 | 2210 | 0.510 |
Why?
|
Continuity of Patient Care | 4 | 2020 | 1049 | 0.500 |
Why?
|
Neoplasm Staging | 30 | 2022 | 11031 | 0.500 |
Why?
|
Aftercare | 2 | 2020 | 866 | 0.500 |
Why?
|
Databases, Factual | 9 | 2021 | 7729 | 0.490 |
Why?
|
Cyclophosphamide | 17 | 2017 | 2242 | 0.490 |
Why?
|
Medicine | 1 | 2023 | 946 | 0.490 |
Why?
|
Peripheral Nervous System Diseases | 6 | 2020 | 685 | 0.480 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2020 | 570 | 0.480 |
Why?
|
Thoracic Neoplasms | 3 | 2021 | 268 | 0.480 |
Why?
|
Health Plan Implementation | 3 | 2014 | 352 | 0.470 |
Why?
|
Pathology, Clinical | 1 | 2017 | 368 | 0.470 |
Why?
|
Human Rights | 1 | 2017 | 307 | 0.470 |
Why?
|
Costs and Cost Analysis | 3 | 2022 | 1681 | 0.460 |
Why?
|
Health Policy | 6 | 2019 | 2661 | 0.460 |
Why?
|
Workload | 2 | 2018 | 850 | 0.450 |
Why?
|
Africa South of the Sahara | 5 | 2023 | 724 | 0.450 |
Why?
|
Middle Aged | 118 | 2024 | 213383 | 0.450 |
Why?
|
Advanced Practice Nursing | 1 | 2013 | 18 | 0.440 |
Why?
|
Neoplasm Recurrence, Local | 20 | 2022 | 9239 | 0.430 |
Why?
|
Benchmarking | 1 | 2019 | 1042 | 0.430 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 8 | 2012 | 1378 | 0.430 |
Why?
|
Specialization | 1 | 2017 | 777 | 0.420 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2019 | 3923 | 0.420 |
Why?
|
Medical Records Systems, Computerized | 4 | 2016 | 1205 | 0.410 |
Why?
|
Rural Health Services | 2 | 2019 | 379 | 0.410 |
Why?
|
Practice Management, Medical | 1 | 2014 | 196 | 0.410 |
Why?
|
Documentation | 4 | 2023 | 871 | 0.410 |
Why?
|
Aged | 90 | 2023 | 163280 | 0.410 |
Why?
|
Tissue Transplantation | 1 | 2012 | 130 | 0.400 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2018 | 255 | 0.400 |
Why?
|
Oncology Service, Hospital | 3 | 2020 | 57 | 0.400 |
Why?
|
Insurance Carriers | 1 | 2013 | 157 | 0.390 |
Why?
|
Medication Errors | 4 | 2012 | 798 | 0.390 |
Why?
|
Poverty | 6 | 2022 | 2660 | 0.390 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 13 | 2023 | 5221 | 0.390 |
Why?
|
Data Collection | 3 | 2015 | 3341 | 0.380 |
Why?
|
Guideline Adherence | 2 | 2019 | 2266 | 0.380 |
Why?
|
Biological Therapy | 1 | 2012 | 138 | 0.380 |
Why?
|
Biomedical Research | 3 | 2023 | 3309 | 0.380 |
Why?
|
Retrospective Studies | 53 | 2023 | 77449 | 0.370 |
Why?
|
Influenza, Human | 1 | 2022 | 1479 | 0.370 |
Why?
|
Disease-Free Survival | 17 | 2021 | 6895 | 0.370 |
Why?
|
Neoplasms, Second Primary | 7 | 2022 | 1061 | 0.370 |
Why?
|
Physician Assistants | 1 | 2013 | 193 | 0.370 |
Why?
|
Cell Transplantation | 1 | 2012 | 477 | 0.360 |
Why?
|
Hematologic Agents | 1 | 2010 | 39 | 0.360 |
Why?
|
Lymphoma, Non-Hodgkin | 6 | 2023 | 1381 | 0.360 |
Why?
|
United States | 32 | 2022 | 69872 | 0.350 |
Why?
|
Nurse Practitioners | 1 | 2013 | 270 | 0.350 |
Why?
|
Radiation Oncology | 3 | 2023 | 555 | 0.350 |
Why?
|
Neoplasms, Unknown Primary | 4 | 2014 | 104 | 0.340 |
Why?
|
Granulocyte Colony-Stimulating Factor | 6 | 2000 | 648 | 0.340 |
Why?
|
Practice Guidelines as Topic | 7 | 2022 | 7279 | 0.330 |
Why?
|
Health Care Costs | 6 | 2021 | 3209 | 0.330 |
Why?
|
Social Class | 1 | 2018 | 1999 | 0.330 |
Why?
|
Health Resources | 6 | 2021 | 911 | 0.330 |
Why?
|
Taxoids | 3 | 2008 | 666 | 0.330 |
Why?
|
Pandemics | 12 | 2023 | 8388 | 0.330 |
Why?
|
Survival Rate | 21 | 2021 | 12788 | 0.320 |
Why?
|
Palliative Care | 6 | 2023 | 3493 | 0.320 |
Why?
|
Nuclear Medicine | 2 | 2022 | 233 | 0.320 |
Why?
|
Adult | 99 | 2023 | 214055 | 0.320 |
Why?
|
Ambulatory Care | 4 | 2021 | 2708 | 0.320 |
Why?
|
Patient-Centered Care | 4 | 2020 | 1439 | 0.310 |
Why?
|
Wilms Tumor | 2 | 2022 | 373 | 0.300 |
Why?
|
Breast | 4 | 2023 | 1969 | 0.300 |
Why?
|
Clinical Pharmacy Information Systems | 1 | 2007 | 103 | 0.300 |
Why?
|
Haiti | 5 | 2022 | 553 | 0.300 |
Why?
|
Models, Organizational | 5 | 2015 | 574 | 0.300 |
Why?
|
Patient Acceptance of Health Care | 3 | 2021 | 3022 | 0.300 |
Why?
|
Medical Order Entry Systems | 2 | 2012 | 545 | 0.300 |
Why?
|
Health Personnel | 6 | 2021 | 3218 | 0.300 |
Why?
|
Male | 94 | 2024 | 350118 | 0.300 |
Why?
|
Mass Screening | 8 | 2023 | 5255 | 0.300 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2014 | 624 | 0.280 |
Why?
|
Patient Care Team | 4 | 2021 | 2531 | 0.280 |
Why?
|
Vinblastine | 5 | 2020 | 502 | 0.280 |
Why?
|
Triage | 4 | 2021 | 976 | 0.280 |
Why?
|
Aged, 80 and over | 36 | 2023 | 57776 | 0.270 |
Why?
|
Health Services Needs and Demand | 7 | 2021 | 1411 | 0.260 |
Why?
|
Coronavirus Infections | 5 | 2020 | 3133 | 0.260 |
Why?
|
Etanidazole | 3 | 1994 | 26 | 0.260 |
Why?
|
Pneumonia, Viral | 5 | 2020 | 3240 | 0.260 |
Why?
|
Societies, Medical | 7 | 2020 | 3743 | 0.260 |
Why?
|
Terminal Care | 3 | 2022 | 1694 | 0.250 |
Why?
|
Quality Improvement | 4 | 2017 | 3749 | 0.250 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2022 | 288 | 0.240 |
Why?
|
Prognosis | 27 | 2022 | 29063 | 0.230 |
Why?
|
Caribbean Region | 2 | 2020 | 194 | 0.230 |
Why?
|
Colectomy | 2 | 2021 | 683 | 0.220 |
Why?
|
Ovary | 1 | 2008 | 981 | 0.220 |
Why?
|
Communication | 6 | 2023 | 3749 | 0.220 |
Why?
|
Behavioral Sciences | 1 | 2022 | 31 | 0.210 |
Why?
|
Adolescent | 26 | 2024 | 85781 | 0.210 |
Why?
|
Socioeconomic Factors | 6 | 2017 | 7785 | 0.210 |
Why?
|
Leukemia, Myeloid, Acute | 4 | 2016 | 3523 | 0.200 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2021 | 68 | 0.200 |
Why?
|
Knowledge | 1 | 2023 | 181 | 0.200 |
Why?
|
Fluorouracil | 9 | 2005 | 1619 | 0.200 |
Why?
|
Treatment Outcome | 32 | 2022 | 63114 | 0.200 |
Why?
|
Forecasting | 4 | 2019 | 2951 | 0.200 |
Why?
|
Mozambique | 1 | 2021 | 54 | 0.190 |
Why?
|
General Practitioners | 1 | 2022 | 103 | 0.190 |
Why?
|
Botswana | 5 | 2024 | 1040 | 0.190 |
Why?
|
Primary Health Care | 1 | 2017 | 4558 | 0.190 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2001 | 692 | 0.190 |
Why?
|
Gynecology | 2 | 2023 | 513 | 0.190 |
Why?
|
Health Maintenance Organizations | 3 | 1992 | 642 | 0.180 |
Why?
|
Medically Underserved Area | 2 | 2014 | 253 | 0.180 |
Why?
|
Private Practice | 1 | 2021 | 154 | 0.180 |
Why?
|
Mitoxantrone | 1 | 2000 | 152 | 0.180 |
Why?
|
Drug Administration Schedule | 10 | 2018 | 4933 | 0.180 |
Why?
|
Isoquinolines | 1 | 2001 | 367 | 0.180 |
Why?
|
Tubulin Modulators | 1 | 2020 | 110 | 0.180 |
Why?
|
Follow-Up Studies | 21 | 2021 | 39050 | 0.180 |
Why?
|
Methotrexate | 8 | 2017 | 1727 | 0.180 |
Why?
|
Bleomycin | 2 | 2020 | 512 | 0.180 |
Why?
|
Infection Control | 2 | 2020 | 966 | 0.180 |
Why?
|
Medical Tourism | 1 | 2020 | 57 | 0.180 |
Why?
|
Referral and Consultation | 6 | 2021 | 3528 | 0.170 |
Why?
|
Health Facilities | 2 | 2022 | 573 | 0.170 |
Why?
|
Triazines | 2 | 1999 | 315 | 0.170 |
Why?
|
Program Development | 3 | 2015 | 1316 | 0.170 |
Why?
|
Radiation-Sensitizing Agents | 2 | 1999 | 358 | 0.170 |
Why?
|
Thoracic Surgical Procedures | 2 | 2020 | 342 | 0.170 |
Why?
|
Pathology, Molecular | 1 | 2022 | 326 | 0.170 |
Why?
|
Models, Biological | 1 | 2016 | 9583 | 0.170 |
Why?
|
Government Regulation | 2 | 2018 | 522 | 0.170 |
Why?
|
Radionuclide Imaging | 3 | 2022 | 2031 | 0.170 |
Why?
|
Lymphatic Metastasis | 6 | 2014 | 2924 | 0.170 |
Why?
|
Young Adult | 14 | 2022 | 56430 | 0.170 |
Why?
|
Africa | 1 | 2021 | 673 | 0.160 |
Why?
|
Hospices | 1 | 2022 | 265 | 0.160 |
Why?
|
Sensory Receptor Cells | 2 | 2014 | 492 | 0.160 |
Why?
|
Consensus | 5 | 2020 | 2959 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 10 | 2023 | 9959 | 0.160 |
Why?
|
Adenocarcinoma | 6 | 2021 | 6364 | 0.160 |
Why?
|
Interdisciplinary Communication | 3 | 2013 | 950 | 0.160 |
Why?
|
Ecosystem | 1 | 2022 | 474 | 0.160 |
Why?
|
Patient Education as Topic | 3 | 2020 | 2278 | 0.160 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 884 | 0.160 |
Why?
|
Quality of Life | 6 | 2023 | 12804 | 0.160 |
Why?
|
Cytarabine | 1 | 2000 | 692 | 0.160 |
Why?
|
Pharmacists | 1 | 2020 | 248 | 0.160 |
Why?
|
Cooperative Behavior | 4 | 2015 | 1504 | 0.160 |
Why?
|
Medical Informatics | 3 | 2019 | 745 | 0.160 |
Why?
|
Whole-Body Irradiation | 1 | 1998 | 449 | 0.150 |
Why?
|
Dacarbazine | 2 | 2020 | 566 | 0.150 |
Why?
|
Hospice Care | 2 | 2022 | 672 | 0.150 |
Why?
|
Receptors, Estrogen | 4 | 2016 | 2187 | 0.150 |
Why?
|
Combined Modality Therapy | 24 | 2019 | 8642 | 0.150 |
Why?
|
Registries | 5 | 2019 | 8089 | 0.150 |
Why?
|
Pilot Projects | 5 | 2024 | 8324 | 0.150 |
Why?
|
Health Priorities | 1 | 2020 | 380 | 0.150 |
Why?
|
Advance Care Planning | 2 | 2022 | 662 | 0.150 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2019 | 841 | 0.150 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 689 | 0.150 |
Why?
|
Outpatients | 2 | 2020 | 1486 | 0.150 |
Why?
|
Reimbursement Mechanisms | 2 | 2021 | 670 | 0.150 |
Why?
|
United States Department of Veterans Affairs | 2 | 2012 | 875 | 0.150 |
Why?
|
Musculoskeletal System | 1 | 2019 | 175 | 0.150 |
Why?
|
Food Supply | 1 | 2022 | 524 | 0.150 |
Why?
|
Advisory Committees | 2 | 2020 | 775 | 0.150 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 501 | 0.140 |
Why?
|
Emigration and Immigration | 1 | 2020 | 404 | 0.140 |
Why?
|
Critical Pathways | 1 | 2020 | 476 | 0.140 |
Why?
|
Career Mobility | 1 | 2019 | 262 | 0.140 |
Why?
|
Poliovirus Vaccine, Oral | 1 | 2016 | 28 | 0.140 |
Why?
|
Cell Hypoxia | 1 | 1999 | 675 | 0.140 |
Why?
|
Abdominal Injuries | 1 | 1999 | 352 | 0.140 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2000 | 640 | 0.140 |
Why?
|
Narration | 2 | 2024 | 212 | 0.140 |
Why?
|
Receptor, erbB-2 | 4 | 2020 | 2416 | 0.140 |
Why?
|
Patients | 1 | 2023 | 900 | 0.140 |
Why?
|
Medical Record Linkage | 2 | 2015 | 284 | 0.140 |
Why?
|
Ovarian Neoplasms | 4 | 2023 | 4838 | 0.140 |
Why?
|
Neoadjuvant Therapy | 4 | 2022 | 2728 | 0.140 |
Why?
|
Vaginal Creams, Foams, and Jellies | 1 | 2015 | 63 | 0.130 |
Why?
|
Delayed Diagnosis | 3 | 2018 | 441 | 0.130 |
Why?
|
Axilla | 3 | 2016 | 595 | 0.130 |
Why?
|
Hysterectomy | 1 | 2021 | 927 | 0.130 |
Why?
|
Cross Infection | 1 | 2005 | 1416 | 0.130 |
Why?
|
Poliomyelitis | 1 | 2016 | 103 | 0.130 |
Why?
|
Pelvis | 1 | 1999 | 730 | 0.130 |
Why?
|
Health Level Seven | 1 | 2015 | 38 | 0.130 |
Why?
|
Medication Systems, Hospital | 1 | 1996 | 158 | 0.130 |
Why?
|
Herpesvirus 4, Human | 1 | 2020 | 1041 | 0.130 |
Why?
|
Survival Analysis | 12 | 2020 | 10252 | 0.130 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2021 | 1101 | 0.120 |
Why?
|
Prednisone | 7 | 2017 | 1574 | 0.120 |
Why?
|
Rescue Work | 1 | 2014 | 56 | 0.120 |
Why?
|
Vincristine | 6 | 2017 | 1039 | 0.120 |
Why?
|
Patient Selection | 3 | 2020 | 4215 | 0.120 |
Why?
|
Breast Diseases | 2 | 2008 | 443 | 0.120 |
Why?
|
Etoposide | 4 | 2007 | 641 | 0.120 |
Why?
|
Cohort Studies | 14 | 2023 | 40561 | 0.120 |
Why?
|
Blue Cross Blue Shield Insurance Plans | 1 | 2014 | 94 | 0.120 |
Why?
|
Life Expectancy | 1 | 2020 | 1184 | 0.120 |
Why?
|
September 11 Terrorist Attacks | 1 | 2014 | 113 | 0.120 |
Why?
|
Publishing | 1 | 2021 | 833 | 0.120 |
Why?
|
Respiration, Artificial | 1 | 2005 | 2569 | 0.120 |
Why?
|
Cyclohexanols | 1 | 2014 | 127 | 0.120 |
Why?
|
Information Systems | 1 | 1996 | 410 | 0.110 |
Why?
|
Thoracic Surgery | 1 | 2020 | 719 | 0.110 |
Why?
|
Mammography | 3 | 2023 | 2476 | 0.110 |
Why?
|
Age Factors | 6 | 2020 | 18370 | 0.110 |
Why?
|
Occult Blood | 3 | 1992 | 176 | 0.110 |
Why?
|
Paroxetine | 1 | 2014 | 182 | 0.110 |
Why?
|
Ultrasonography, Mammary | 2 | 2022 | 250 | 0.110 |
Why?
|
Hospitals, Veterans | 2 | 2012 | 404 | 0.110 |
Why?
|
Infusions, Intravenous | 9 | 2008 | 2274 | 0.110 |
Why?
|
Sexual Partners | 2 | 2015 | 730 | 0.110 |
Why?
|
Wounds, Nonpenetrating | 1 | 1999 | 794 | 0.110 |
Why?
|
Bone Density Conservation Agents | 1 | 2020 | 773 | 0.110 |
Why?
|
Pneumonia | 1 | 2005 | 2133 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.110 |
Why?
|
Private Sector | 2 | 2013 | 392 | 0.110 |
Why?
|
HIV Infections | 5 | 2022 | 16718 | 0.110 |
Why?
|
Alkylating Agents | 1 | 1993 | 139 | 0.110 |
Why?
|
Telemedicine | 3 | 2021 | 2872 | 0.110 |
Why?
|
Burnout, Professional | 1 | 2021 | 694 | 0.110 |
Why?
|
Medication Adherence | 1 | 2024 | 2063 | 0.100 |
Why?
|
GRB7 Adaptor Protein | 1 | 2011 | 3 | 0.100 |
Why?
|
Remission Induction | 7 | 2007 | 2386 | 0.100 |
Why?
|
Biomedical Technology | 1 | 2014 | 220 | 0.100 |
Why?
|
Smoking | 4 | 2023 | 8987 | 0.100 |
Why?
|
Leadership | 2 | 2020 | 1357 | 0.100 |
Why?
|
Accreditation | 1 | 2015 | 450 | 0.100 |
Why?
|
Teaching | 1 | 2019 | 1174 | 0.100 |
Why?
|
Caregivers | 2 | 2020 | 2094 | 0.100 |
Why?
|
Diagnosis-Related Groups | 1 | 2013 | 455 | 0.100 |
Why?
|
Public Sector | 1 | 2013 | 265 | 0.100 |
Why?
|
Electronic Prescribing | 1 | 2012 | 121 | 0.100 |
Why?
|
Risk Assessment | 5 | 2022 | 23338 | 0.100 |
Why?
|
Intensive Care Units | 1 | 2005 | 3679 | 0.100 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 25043 | 0.100 |
Why?
|
Patient Satisfaction | 2 | 2019 | 3396 | 0.100 |
Why?
|
Genetic Research | 1 | 2012 | 174 | 0.100 |
Why?
|
Carboplatin | 4 | 2021 | 801 | 0.100 |
Why?
|
Incidence | 9 | 2019 | 20947 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 6 | 2008 | 20129 | 0.100 |
Why?
|
Disease Management | 3 | 2020 | 2459 | 0.090 |
Why?
|
Physician's Role | 1 | 2018 | 943 | 0.090 |
Why?
|
Risk Factors | 15 | 2021 | 72290 | 0.090 |
Why?
|
Lymphoma, B-Cell | 2 | 1998 | 931 | 0.090 |
Why?
|
Drug Therapy, Computer-Assisted | 1 | 2012 | 204 | 0.090 |
Why?
|
Long-Term Care | 1 | 2014 | 607 | 0.090 |
Why?
|
Leukemia | 3 | 2012 | 1511 | 0.090 |
Why?
|
Preoperative Care | 1 | 2019 | 2250 | 0.090 |
Why?
|
Insurance Coverage | 2 | 2020 | 1901 | 0.090 |
Why?
|
Mastectomy | 4 | 2022 | 1793 | 0.090 |
Why?
|
Databases as Topic | 1 | 2012 | 475 | 0.090 |
Why?
|
Prospective Studies | 15 | 2022 | 53288 | 0.090 |
Why?
|
Medicaid | 2 | 2021 | 2736 | 0.090 |
Why?
|
Kaplan-Meier Estimate | 6 | 2021 | 6538 | 0.090 |
Why?
|
Healthcare Disparities | 3 | 2021 | 3158 | 0.090 |
Why?
|
Fee-for-Service Plans | 2 | 2012 | 694 | 0.090 |
Why?
|
Clinical Competence | 2 | 2023 | 4687 | 0.090 |
Why?
|
Drug Costs | 1 | 2017 | 1105 | 0.090 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1209 | 0.090 |
Why?
|
Efficiency | 1 | 2013 | 462 | 0.090 |
Why?
|
Myelodysplastic Syndromes | 2 | 2016 | 1352 | 0.090 |
Why?
|
Neutropenia | 4 | 2000 | 895 | 0.080 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 2282 | 0.080 |
Why?
|
Stomach Neoplasms | 1 | 2018 | 1333 | 0.080 |
Why?
|
Time Factors | 17 | 2021 | 40075 | 0.080 |
Why?
|
Attitude of Health Personnel | 1 | 2023 | 3843 | 0.080 |
Why?
|
Safety Management | 2 | 2012 | 783 | 0.080 |
Why?
|
Prostatic Neoplasms | 2 | 2023 | 11124 | 0.080 |
Why?
|
Camptothecin | 3 | 1998 | 576 | 0.080 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1038 | 0.080 |
Why?
|
Brazil | 1 | 2013 | 1270 | 0.080 |
Why?
|
Laparoscopy | 1 | 2021 | 2151 | 0.080 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 1519 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 2 | 2015 | 2232 | 0.080 |
Why?
|
Cost Savings | 1 | 2014 | 926 | 0.080 |
Why?
|
Proportional Hazards Models | 6 | 2023 | 12354 | 0.080 |
Why?
|
Problem Solving | 1 | 2011 | 440 | 0.080 |
Why?
|
Interprofessional Relations | 1 | 2014 | 1011 | 0.080 |
Why?
|
Anemia, Hypochromic | 1 | 1988 | 66 | 0.080 |
Why?
|
Administration, Oral | 3 | 2012 | 3913 | 0.080 |
Why?
|
Medical Errors | 2 | 2015 | 1297 | 0.080 |
Why?
|
Multiple Myeloma | 3 | 2012 | 5181 | 0.080 |
Why?
|
Workflow | 1 | 2013 | 847 | 0.080 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2014 | 806 | 0.080 |
Why?
|
Infant | 7 | 2019 | 35136 | 0.080 |
Why?
|
New York City | 2 | 2014 | 710 | 0.080 |
Why?
|
Computer Simulation | 1 | 2021 | 6196 | 0.080 |
Why?
|
Salvage Therapy | 5 | 1995 | 1275 | 0.080 |
Why?
|
Sexual Behavior | 2 | 2015 | 2057 | 0.080 |
Why?
|
Child, Preschool | 11 | 2022 | 41006 | 0.080 |
Why?
|
Hemoglobins, Abnormal | 1 | 1988 | 119 | 0.080 |
Why?
|
Radiotherapy Dosage | 7 | 1999 | 2879 | 0.080 |
Why?
|
Tobacco Industry | 2 | 2006 | 126 | 0.080 |
Why?
|
Patient Transfer | 1 | 2014 | 761 | 0.080 |
Why?
|
Biopsy | 3 | 2019 | 6756 | 0.080 |
Why?
|
Growth Hormone | 1 | 1990 | 705 | 0.080 |
Why?
|
Mediastinal Diseases | 1 | 2008 | 89 | 0.080 |
Why?
|
Polyglutamic Acid | 1 | 2007 | 44 | 0.070 |
Why?
|
Muscle Cramp | 2 | 1999 | 35 | 0.070 |
Why?
|
Mesna | 2 | 1998 | 66 | 0.070 |
Why?
|
Policy | 2 | 2022 | 508 | 0.070 |
Why?
|
Aspirin | 1 | 2019 | 3282 | 0.070 |
Why?
|
Thrombocytopenia | 5 | 2000 | 1179 | 0.070 |
Why?
|
Organizational Case Studies | 1 | 2007 | 299 | 0.070 |
Why?
|
Child | 15 | 2022 | 77709 | 0.070 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 973 | 0.070 |
Why?
|
Mexico | 2 | 2010 | 690 | 0.070 |
Why?
|
Recurrence | 9 | 2017 | 8340 | 0.070 |
Why?
|
Drug Eruptions | 2 | 2000 | 297 | 0.070 |
Why?
|
Dental Implantation, Endosseous | 1 | 1990 | 502 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 3507 | 0.070 |
Why?
|
Anti-Bacterial Agents | 1 | 2005 | 7181 | 0.070 |
Why?
|
Sudden Infant Death | 1 | 2009 | 291 | 0.070 |
Why?
|
Multifactorial Inheritance | 1 | 2014 | 1194 | 0.070 |
Why?
|
Attitude to Health | 1 | 2015 | 2052 | 0.070 |
Why?
|
Bone Marrow | 4 | 1995 | 2948 | 0.070 |
Why?
|
Ifosfamide | 2 | 1998 | 228 | 0.070 |
Why?
|
Neoplasm Metastasis | 7 | 2008 | 4851 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2020 | 15519 | 0.070 |
Why?
|
Uganda | 2 | 2022 | 1243 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4034 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 2008 | 440 | 0.070 |
Why?
|
Axons | 1 | 2014 | 1684 | 0.070 |
Why?
|
Edema | 2 | 2008 | 789 | 0.070 |
Why?
|
Kidney Neoplasms | 1 | 2022 | 4262 | 0.070 |
Why?
|
Informed Consent | 1 | 2012 | 995 | 0.070 |
Why?
|
Tachycardia | 1 | 2008 | 619 | 0.070 |
Why?
|
Logistic Models | 5 | 2021 | 13408 | 0.060 |
Why?
|
Massachusetts | 4 | 2014 | 8663 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 1993 | 1988 | 0.060 |
Why?
|
Parkinson Disease | 2 | 2014 | 2775 | 0.060 |
Why?
|
Urban Population | 1 | 2013 | 2021 | 0.060 |
Why?
|
Gene Dosage | 1 | 2009 | 1252 | 0.060 |
Why?
|
Treatment Failure | 2 | 2009 | 2618 | 0.060 |
Why?
|
Central America | 1 | 2004 | 68 | 0.060 |
Why?
|
Dominican Republic | 1 | 2004 | 76 | 0.060 |
Why?
|
Standard of Care | 2 | 2019 | 564 | 0.060 |
Why?
|
Radiology, Interventional | 1 | 2008 | 460 | 0.060 |
Why?
|
Prescriptions | 2 | 2021 | 387 | 0.060 |
Why?
|
Occupational Exposure | 1 | 2014 | 1796 | 0.060 |
Why?
|
Vaccination | 1 | 2016 | 3278 | 0.060 |
Why?
|
Angiography | 2 | 1999 | 1639 | 0.060 |
Why?
|
Boston | 5 | 2008 | 9313 | 0.060 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5391 | 0.060 |
Why?
|
Medicare | 2 | 2012 | 6566 | 0.060 |
Why?
|
Sample Size | 1 | 2007 | 845 | 0.060 |
Why?
|
Catheterization, Central Venous | 1 | 2008 | 514 | 0.060 |
Why?
|
Granulocytes | 2 | 1995 | 548 | 0.060 |
Why?
|
Radiotherapy | 4 | 2018 | 1533 | 0.060 |
Why?
|
Genome-Wide Association Study | 4 | 2020 | 12261 | 0.050 |
Why?
|
Adenovirus E1B Proteins | 1 | 2002 | 15 | 0.050 |
Why?
|
Outpatient Clinics, Hospital | 1 | 2005 | 392 | 0.050 |
Why?
|
Antigens, CD | 1 | 1993 | 4026 | 0.050 |
Why?
|
Dental Implants | 1 | 1990 | 749 | 0.050 |
Why?
|
Decision Making, Organizational | 1 | 2003 | 139 | 0.050 |
Why?
|
Research | 2 | 2022 | 1999 | 0.050 |
Why?
|
Anticoagulants | 2 | 2012 | 4599 | 0.050 |
Why?
|
Colorectal Neoplasms | 2 | 1992 | 6773 | 0.050 |
Why?
|
Sarcoidosis | 1 | 2007 | 506 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2008 | 12959 | 0.050 |
Why?
|
Antidepressive Agents | 1 | 2014 | 2838 | 0.050 |
Why?
|
Cells, Cultured | 5 | 2020 | 19229 | 0.050 |
Why?
|
Predictive Value of Tests | 5 | 2019 | 15076 | 0.050 |
Why?
|
Total Quality Management | 1 | 2003 | 274 | 0.050 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2014 | 1813 | 0.050 |
Why?
|
Capital Expenditures | 1 | 2021 | 29 | 0.050 |
Why?
|
West Nile Fever | 1 | 2001 | 81 | 0.050 |
Why?
|
Rectal Neoplasms | 2 | 2012 | 1206 | 0.050 |
Why?
|
Philadelphia | 1 | 2021 | 266 | 0.050 |
Why?
|
Stress, Psychological | 1 | 2016 | 4245 | 0.050 |
Why?
|
Transportation | 1 | 2022 | 214 | 0.050 |
Why?
|
Malawi | 2 | 2013 | 282 | 0.050 |
Why?
|
Cisplatin | 6 | 2007 | 1662 | 0.050 |
Why?
|
Israel | 3 | 2016 | 796 | 0.050 |
Why?
|
Sexually Transmitted Diseases | 1 | 2007 | 624 | 0.050 |
Why?
|
Safety | 1 | 2005 | 1186 | 0.050 |
Why?
|
Child Language | 1 | 2001 | 64 | 0.050 |
Why?
|
DNA | 2 | 1993 | 7301 | 0.050 |
Why?
|
Africa, Eastern | 1 | 2020 | 71 | 0.050 |
Why?
|
Poliovirus Vaccine, Inactivated | 2 | 2016 | 24 | 0.050 |
Why?
|
Zoonoses | 1 | 2001 | 185 | 0.050 |
Why?
|
Government Programs | 1 | 2022 | 275 | 0.050 |
Why?
|
Hematologic Neoplasms | 1 | 2012 | 1832 | 0.050 |
Why?
|
Neoplasm Invasiveness | 3 | 2020 | 3616 | 0.050 |
Why?
|
Radiography | 2 | 2022 | 7023 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 4 | 1995 | 3386 | 0.050 |
Why?
|
Kenya | 1 | 2022 | 685 | 0.050 |
Why?
|
Technology | 1 | 2022 | 305 | 0.040 |
Why?
|
Language Disorders | 1 | 2001 | 141 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2020 | 105 | 0.040 |
Why?
|
Culture | 1 | 2004 | 633 | 0.040 |
Why?
|
SEER Program | 2 | 2017 | 1508 | 0.040 |
Why?
|
Dyspnea | 1 | 2008 | 1303 | 0.040 |
Why?
|
Tobacco Use Disorder | 1 | 2006 | 688 | 0.040 |
Why?
|
Sleep Apnea Syndromes | 1 | 2008 | 944 | 0.040 |
Why?
|
Radioactive Hazard Release | 1 | 2019 | 14 | 0.040 |
Why?
|
Folic Acid Antagonists | 1 | 2000 | 84 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2008 | 3508 | 0.040 |
Why?
|
Peer Review, Research | 1 | 2023 | 329 | 0.040 |
Why?
|
Disease Outbreaks | 2 | 2016 | 1772 | 0.040 |
Why?
|
Anxiety | 1 | 2014 | 4297 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2007 | 972 | 0.040 |
Why?
|
Federal Government | 1 | 2021 | 260 | 0.040 |
Why?
|
Patient Compliance | 2 | 2007 | 2684 | 0.040 |
Why?
|
Acetamides | 1 | 2001 | 249 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19905 | 0.040 |
Why?
|
Poliovirus | 1 | 1999 | 109 | 0.040 |
Why?
|
Lymphoma | 1 | 2008 | 1877 | 0.040 |
Why?
|
Guanine | 1 | 2000 | 274 | 0.040 |
Why?
|
Hospitals, Community | 1 | 2021 | 348 | 0.040 |
Why?
|
Glutamates | 1 | 2000 | 398 | 0.040 |
Why?
|
Blast Crisis | 1 | 1998 | 103 | 0.040 |
Why?
|
Phlebography | 1 | 1999 | 333 | 0.040 |
Why?
|
User-Computer Interface | 2 | 2015 | 1431 | 0.040 |
Why?
|
Veterans | 1 | 2012 | 2519 | 0.040 |
Why?
|
Neurites | 1 | 2020 | 388 | 0.040 |
Why?
|
Morals | 1 | 2021 | 284 | 0.040 |
Why?
|
American Cancer Society | 1 | 2017 | 61 | 0.040 |
Why?
|
Neoplasms, Ductal, Lobular, and Medullary | 1 | 1997 | 1 | 0.040 |
Why?
|
Death | 1 | 2023 | 678 | 0.040 |
Why?
|
Genotype | 3 | 2023 | 12951 | 0.040 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2006 | 2948 | 0.040 |
Why?
|
Laparotomy | 3 | 1995 | 473 | 0.040 |
Why?
|
Housing | 1 | 2022 | 664 | 0.040 |
Why?
|
Cerebellar Diseases | 1 | 2000 | 226 | 0.040 |
Why?
|
Mastectomy, Radical | 2 | 1997 | 20 | 0.040 |
Why?
|
South Africa | 1 | 2023 | 1731 | 0.040 |
Why?
|
Platelet Count | 2 | 1998 | 781 | 0.040 |
Why?
|
Delphi Technique | 1 | 2020 | 778 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2000 | 1420 | 0.040 |
Why?
|
South America | 1 | 2017 | 181 | 0.040 |
Why?
|
Women's Health | 1 | 2007 | 2034 | 0.040 |
Why?
|
Medical Informatics Applications | 1 | 2019 | 186 | 0.040 |
Why?
|
Receptors, Progesterone | 2 | 2012 | 1097 | 0.040 |
Why?
|
Biology | 1 | 2019 | 294 | 0.040 |
Why?
|
Travel | 1 | 2023 | 788 | 0.040 |
Why?
|
Income | 2 | 2020 | 1913 | 0.040 |
Why?
|
Bone Marrow Cells | 2 | 1991 | 2513 | 0.040 |
Why?
|
Vena Cava Filters | 1 | 1999 | 252 | 0.040 |
Why?
|
Interferon Type I | 3 | 1985 | 542 | 0.040 |
Why?
|
Mediastinum | 1 | 1998 | 267 | 0.040 |
Why?
|
Gallium Radioisotopes | 1 | 1997 | 178 | 0.040 |
Why?
|
Asparaginase | 1 | 2017 | 236 | 0.030 |
Why?
|
Obesity | 1 | 2018 | 12745 | 0.030 |
Why?
|
Lymphoma, Large-Cell, Immunoblastic | 1 | 1995 | 26 | 0.030 |
Why?
|
Pharmacogenetics | 1 | 2020 | 675 | 0.030 |
Why?
|
Catheterization, Peripheral | 1 | 1999 | 345 | 0.030 |
Why?
|
Exanthema | 1 | 2000 | 501 | 0.030 |
Why?
|
Mentors | 1 | 2020 | 631 | 0.030 |
Why?
|
Helicobacter pylori | 1 | 2018 | 382 | 0.030 |
Why?
|
Program Evaluation | 2 | 2015 | 2488 | 0.030 |
Why?
|
Helicobacter Infections | 1 | 2018 | 386 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2021 | 853 | 0.030 |
Why?
|
Phenotype | 3 | 2022 | 16365 | 0.030 |
Why?
|
Arteries | 1 | 1999 | 1119 | 0.030 |
Why?
|
Pancreatic Neoplasms | 2 | 2004 | 5256 | 0.030 |
Why?
|
Anthracyclines | 1 | 2016 | 288 | 0.030 |
Why?
|
Arabs | 1 | 2016 | 178 | 0.030 |
Why?
|
Body Mass Index | 2 | 2023 | 12720 | 0.030 |
Why?
|
Choice Behavior | 1 | 2020 | 803 | 0.030 |
Why?
|
Depression | 1 | 2014 | 7766 | 0.030 |
Why?
|
Biopsy, Fine-Needle | 1 | 2019 | 1094 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 725 | 0.030 |
Why?
|
Blood Specimen Collection | 1 | 1995 | 246 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2020 | 1119 | 0.030 |
Why?
|
Dexamethasone | 2 | 2017 | 1951 | 0.030 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12245 | 0.030 |
Why?
|
Collagen | 1 | 2002 | 2689 | 0.030 |
Why?
|
Mastectomy, Simple | 1 | 1993 | 24 | 0.030 |
Why?
|
Hospitals, Rural | 1 | 2015 | 172 | 0.030 |
Why?
|
Carcinoma, Small Cell | 2 | 2012 | 420 | 0.030 |
Why?
|
Patient Participation | 1 | 2003 | 1457 | 0.030 |
Why?
|
Occupational Health | 1 | 2020 | 809 | 0.030 |
Why?
|
Health Education | 1 | 2020 | 1056 | 0.030 |
Why?
|
Interleukin-3 | 1 | 1994 | 444 | 0.030 |
Why?
|
Anti-Infective Agents, Local | 1 | 2015 | 250 | 0.030 |
Why?
|
Digestive System Surgical Procedures | 1 | 2018 | 576 | 0.030 |
Why?
|
Anemia, Refractory | 1 | 1992 | 17 | 0.030 |
Why?
|
Macrophages | 3 | 1995 | 5655 | 0.030 |
Why?
|
Thromboembolism | 1 | 1999 | 986 | 0.030 |
Why?
|
Receptor, EphA5 | 1 | 2012 | 11 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2015 | 977 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 1738 | 0.030 |
Why?
|
Systems Integration | 1 | 2015 | 440 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2009 | 13989 | 0.030 |
Why?
|
Hypotension | 1 | 1999 | 884 | 0.030 |
Why?
|
Republic of Korea | 1 | 2015 | 539 | 0.030 |
Why?
|
Teleradiology | 1 | 2013 | 53 | 0.030 |
Why?
|
Risk | 3 | 2016 | 9687 | 0.030 |
Why?
|
Environmental Monitoring | 1 | 1999 | 1414 | 0.030 |
Why?
|
Melphalan | 1 | 1994 | 431 | 0.030 |
Why?
|
Mutagens | 1 | 1993 | 168 | 0.030 |
Why?
|
Telepathology | 1 | 2013 | 76 | 0.030 |
Why?
|
Angiogenesis Inhibitors | 1 | 2002 | 2038 | 0.030 |
Why?
|
Ethics Committees | 1 | 2012 | 54 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2008 | 8428 | 0.030 |
Why?
|
Medical Audit | 1 | 2013 | 467 | 0.030 |
Why?
|
Pregnancy | 2 | 2018 | 29144 | 0.030 |
Why?
|
Anemia, Sideroblastic | 1 | 1992 | 101 | 0.030 |
Why?
|
Disease Progression | 2 | 2007 | 13284 | 0.030 |
Why?
|
Child Mortality | 1 | 2014 | 198 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2000 | 1541 | 0.030 |
Why?
|
Blood Coagulation Tests | 1 | 2012 | 263 | 0.030 |
Why?
|
Reoperation | 1 | 2021 | 4201 | 0.020 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 1995 | 547 | 0.020 |
Why?
|
Cost of Illness | 1 | 2021 | 1859 | 0.020 |
Why?
|
Research Support as Topic | 1 | 2015 | 705 | 0.020 |
Why?
|
Genetic Testing | 1 | 2023 | 3444 | 0.020 |
Why?
|
Clinical Trials as Topic | 2 | 2008 | 7913 | 0.020 |
Why?
|
Mastication | 1 | 1990 | 53 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2012 | 17446 | 0.020 |
Why?
|
Jordan | 1 | 2010 | 74 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 1998 | 5442 | 0.020 |
Why?
|
Health Planning Guidelines | 1 | 2011 | 163 | 0.020 |
Why?
|
Risk-Taking | 1 | 2015 | 986 | 0.020 |
Why?
|
Least-Squares Analysis | 1 | 1990 | 379 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2002 | 5097 | 0.020 |
Why?
|
Colombia | 1 | 2010 | 258 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1656 | 0.020 |
Why?
|
Colony-Forming Units Assay | 2 | 1995 | 356 | 0.020 |
Why?
|
Ultrasonography | 2 | 2020 | 5985 | 0.020 |
Why?
|
Cause of Death | 1 | 2000 | 3584 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2000 | 10943 | 0.020 |
Why?
|
Lymphocytes | 1 | 1997 | 2617 | 0.020 |
Why?
|
Hepatitis B Vaccines | 1 | 2010 | 194 | 0.020 |
Why?
|
Odds Ratio | 2 | 2012 | 9849 | 0.020 |
Why?
|
Testicular Neoplasms | 1 | 1995 | 804 | 0.020 |
Why?
|
Turner Syndrome | 1 | 1990 | 130 | 0.020 |
Why?
|
Thrombocythemia, Essential | 1 | 1990 | 105 | 0.020 |
Why?
|
Mutagenesis | 1 | 1993 | 1266 | 0.020 |
Why?
|
Chromosomes, Human, 4-5 | 2 | 1985 | 28 | 0.020 |
Why?
|
Esthetics, Dental | 1 | 1990 | 250 | 0.020 |
Why?
|
Comorbidity | 2 | 2014 | 10388 | 0.020 |
Why?
|
Algorithms | 3 | 2022 | 13881 | 0.020 |
Why?
|
Patient Advocacy | 1 | 2011 | 353 | 0.020 |
Why?
|
Interferons | 2 | 1984 | 706 | 0.020 |
Why?
|
Cell Division | 3 | 1983 | 4568 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2012 | 780 | 0.020 |
Why?
|
Tamoxifen | 3 | 1997 | 981 | 0.020 |
Why?
|
Rural Health | 1 | 2010 | 305 | 0.020 |
Why?
|
Erythropoietin | 1 | 2012 | 726 | 0.020 |
Why?
|
Polysomnography | 1 | 2014 | 1776 | 0.020 |
Why?
|
Comparative Genomic Hybridization | 1 | 2009 | 496 | 0.020 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 810 | 0.020 |
Why?
|
Gastroesophageal Reflux | 1 | 2014 | 782 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2012 | 1152 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 602 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 4 | 2023 | 35421 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2006 | 3870 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4445 | 0.020 |
Why?
|
Mutation | 2 | 2014 | 29786 | 0.020 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2010 | 469 | 0.020 |
Why?
|
Health Services Research | 1 | 2014 | 1836 | 0.020 |
Why?
|
Severity of Illness Index | 3 | 2014 | 15540 | 0.020 |
Why?
|
Cell Count | 2 | 1983 | 1856 | 0.020 |
Why?
|
Decision Making | 1 | 2020 | 3887 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2020 | 3229 | 0.020 |
Why?
|
Psychometrics | 1 | 2015 | 3002 | 0.020 |
Why?
|
Heart | 1 | 1999 | 4467 | 0.020 |
Why?
|
Deltaretrovirus | 1 | 1985 | 170 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6459 | 0.020 |
Why?
|
Actuarial Analysis | 2 | 1996 | 378 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2008 | 15295 | 0.020 |
Why?
|
Sampling Studies | 1 | 2007 | 623 | 0.020 |
Why?
|
Sinusitis | 1 | 2014 | 923 | 0.020 |
Why?
|
New York | 1 | 2008 | 886 | 0.020 |
Why?
|
Gene Expression Profiling | 2 | 2014 | 9438 | 0.020 |
Why?
|
Self Report | 1 | 2016 | 3558 | 0.020 |
Why?
|
Retroviridae Infections | 1 | 1985 | 151 | 0.020 |
Why?
|
Time Management | 1 | 2005 | 50 | 0.020 |
Why?
|
Chromosomes, Human, 21-22 and Y | 1 | 1984 | 46 | 0.020 |
Why?
|
Growth Disorders | 1 | 1990 | 645 | 0.020 |
Why?
|
Double-Blind Method | 2 | 2014 | 12026 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2012 | 2019 | 0.020 |
Why?
|
Infant, Newborn | 2 | 2019 | 25625 | 0.020 |
Why?
|
Time and Motion Studies | 1 | 2005 | 149 | 0.020 |
Why?
|
Oximetry | 1 | 2008 | 471 | 0.020 |
Why?
|
Community Health Services | 1 | 2010 | 650 | 0.020 |
Why?
|
Tobacco Use Cessation | 1 | 2006 | 95 | 0.020 |
Why?
|
Streptozocin | 1 | 2004 | 196 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2009 | 1850 | 0.020 |
Why?
|
Procarbazine | 2 | 1994 | 181 | 0.020 |
Why?
|
Mechlorethamine | 2 | 1994 | 136 | 0.020 |
Why?
|
Medical Records | 2 | 1990 | 1413 | 0.020 |
Why?
|
Propensity Score | 1 | 2011 | 1781 | 0.020 |
Why?
|
International Cooperation | 1 | 2011 | 1420 | 0.020 |
Why?
|
Warfarin | 1 | 2012 | 1496 | 0.010 |
Why?
|
Papillomavirus Vaccines | 1 | 2010 | 491 | 0.010 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 2 | 2001 | 1107 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2010 | 956 | 0.010 |
Why?
|
Leucovorin | 2 | 1997 | 628 | 0.010 |
Why?
|
Tobacco, Smokeless | 1 | 2004 | 130 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2014 | 6038 | 0.010 |
Why?
|
Esophageal Neoplasms | 1 | 2013 | 1583 | 0.010 |
Why?
|
Antibodies | 1 | 2011 | 2460 | 0.010 |
Why?
|
Immunohistochemistry | 2 | 2007 | 11366 | 0.010 |
Why?
|
Mass Media | 1 | 2006 | 305 | 0.010 |
Why?
|
Prosthesis Failure | 1 | 2008 | 1206 | 0.010 |
Why?
|
Virus Replication | 2 | 2002 | 2534 | 0.010 |
Why?
|
Genetic Loci | 1 | 2012 | 2575 | 0.010 |
Why?
|
Antibodies, Viral | 2 | 2002 | 3176 | 0.010 |
Why?
|
Health Facility Merger | 1 | 2003 | 53 | 0.010 |
Why?
|
Thymidine | 1 | 1982 | 310 | 0.010 |
Why?
|
Peritoneal Cavity | 1 | 1982 | 148 | 0.010 |
Why?
|
Qualitative Research | 1 | 2011 | 2682 | 0.010 |
Why?
|
Geese | 1 | 2001 | 19 | 0.010 |
Why?
|
Endostatins | 1 | 2002 | 174 | 0.010 |
Why?
|
Databases, Genetic | 1 | 2009 | 1783 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 1984 | 457 | 0.010 |
Why?
|
Analysis of Variance | 1 | 1990 | 6365 | 0.010 |
Why?
|
Transplantation, Autologous | 2 | 1998 | 2124 | 0.010 |
Why?
|
Injections, Intraperitoneal | 1 | 2002 | 425 | 0.010 |
Why?
|
Landau-Kleffner Syndrome | 1 | 2001 | 12 | 0.010 |
Why?
|
West Nile virus | 1 | 2001 | 82 | 0.010 |
Why?
|
Models, Statistical | 1 | 2016 | 5102 | 0.010 |
Why?
|
Heterozygote | 1 | 1988 | 2804 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2002 | 772 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7659 | 0.010 |
Why?
|
Language Tests | 1 | 2001 | 200 | 0.010 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2013 | 2245 | 0.010 |
Why?
|
Hybrid Cells | 3 | 1985 | 441 | 0.010 |
Why?
|
Polynucleotide Ligases | 1 | 1980 | 2 | 0.010 |
Why?
|
Diffusion | 1 | 1982 | 833 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 2001 | 401 | 0.010 |
Why?
|
Receptors, Glutamate | 1 | 2001 | 232 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2002 | 599 | 0.010 |
Why?
|
Carcinoma in Situ | 1 | 2006 | 806 | 0.010 |
Why?
|
Bleeding Time | 1 | 1999 | 89 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2002 | 694 | 0.010 |
Why?
|
Genes | 1 | 1984 | 1893 | 0.010 |
Why?
|
Carcinoma | 1 | 2011 | 2375 | 0.010 |
Why?
|
Crohn Disease | 1 | 1992 | 2303 | 0.010 |
Why?
|
Physical Examination | 1 | 1986 | 1237 | 0.010 |
Why?
|
Organizational Innovation | 1 | 2003 | 559 | 0.010 |
Why?
|
Verbal Behavior | 1 | 2001 | 339 | 0.010 |
Why?
|
Sewage | 1 | 1999 | 40 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2007 | 2453 | 0.010 |
Why?
|
Iron | 1 | 1988 | 1774 | 0.010 |
Why?
|
Lymphokines | 1 | 2002 | 949 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 2002 | 6622 | 0.010 |
Why?
|
Animals | 10 | 2001 | 168757 | 0.010 |
Why?
|
Middle East | 1 | 1999 | 219 | 0.010 |
Why?
|
Gene Expression | 1 | 2011 | 7799 | 0.010 |
Why?
|
Skin Neoplasms | 1 | 1998 | 5686 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2010 | 2071 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 2008 | 9274 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2002 | 2327 | 0.010 |
Why?
|
Hemorrhage | 1 | 1990 | 3461 | 0.010 |
Why?
|
Colloids | 1 | 1998 | 136 | 0.010 |
Why?
|
Insurance, Health | 1 | 2010 | 2494 | 0.010 |
Why?
|
Adenoviridae | 1 | 2002 | 1099 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4253 | 0.010 |
Why?
|
Autoantibodies | 1 | 2006 | 2035 | 0.010 |
Why?
|
Antigens, Viral | 1 | 2001 | 1035 | 0.010 |
Why?
|
Health Status | 1 | 1990 | 4034 | 0.010 |
Why?
|
Public Health | 1 | 2010 | 2603 | 0.010 |
Why?
|
Creatinine | 1 | 2002 | 1919 | 0.010 |
Why?
|
Geography | 1 | 1999 | 669 | 0.010 |
Why?
|
Chemistry, Pharmaceutical | 1 | 1998 | 281 | 0.010 |
Why?
|
Radiation Pneumonitis | 1 | 1997 | 104 | 0.010 |
Why?
|
DNA Topoisomerases, Type I | 1 | 1996 | 102 | 0.010 |
Why?
|
Urban Health | 1 | 1999 | 547 | 0.010 |
Why?
|
Antidotes | 1 | 1997 | 138 | 0.010 |
Why?
|
False Negative Reactions | 1 | 1997 | 588 | 0.010 |
Why?
|
Mice | 8 | 1991 | 81183 | 0.010 |
Why?
|
Arm | 1 | 1999 | 589 | 0.010 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1998 | 876 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2012 | 16689 | 0.010 |
Why?
|
Thrombosis | 1 | 1990 | 2968 | 0.010 |
Why?
|
Genome, Human | 1 | 2009 | 4420 | 0.010 |
Why?
|
Child Behavior Disorders | 1 | 2001 | 807 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2001 | 1677 | 0.010 |
Why?
|
Interferon-gamma | 1 | 1984 | 3206 | 0.010 |
Why?
|
Age Distribution | 1 | 2001 | 2902 | 0.010 |
Why?
|
Leukapheresis | 1 | 1995 | 131 | 0.010 |
Why?
|
Radiation Dosage | 1 | 2004 | 1928 | 0.010 |
Why?
|
Interpersonal Relations | 1 | 2003 | 1425 | 0.010 |
Why?
|
Thoracotomy | 1 | 1997 | 363 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2012 | 9648 | 0.010 |
Why?
|
Software | 1 | 2009 | 4443 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 1984 | 2866 | 0.010 |
Why?
|
Length of Stay | 1 | 2008 | 6309 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4751 | 0.010 |
Why?
|
Thorax | 1 | 1997 | 547 | 0.010 |
Why?
|
Topotecan | 1 | 1994 | 137 | 0.010 |
Why?
|
Drug Tolerance | 1 | 1995 | 376 | 0.010 |
Why?
|
Antigens, CD34 | 1 | 1995 | 657 | 0.010 |
Why?
|
Seasons | 1 | 1999 | 1493 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1982 | 2969 | 0.010 |
Why?
|
Nucleic Acid Hybridization | 2 | 1985 | 1375 | 0.010 |
Why?
|
Transcription Factors | 1 | 2012 | 12208 | 0.010 |
Why?
|
Chromosomes, Human, Pair 20 | 1 | 1992 | 133 | 0.010 |
Why?
|
Refugees | 1 | 1999 | 511 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1995 | 1588 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2007 | 6234 | 0.010 |
Why?
|
Cricetinae | 2 | 1985 | 2472 | 0.010 |
Why?
|
Karyotyping | 1 | 1992 | 1243 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2000 | 6489 | 0.010 |
Why?
|
Nitroimidazoles | 1 | 1991 | 106 | 0.010 |
Why?
|
Drug Evaluation | 1 | 1991 | 647 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1991 | 964 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1997 | 1524 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2001 | 1912 | 0.010 |
Why?
|
Fibrosarcoma | 1 | 1991 | 348 | 0.010 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 1991 | 730 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1977 | 2072 | 0.000 |
Why?
|
Bone Marrow Transplantation | 1 | 1995 | 2765 | 0.000 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2002 | 5172 | 0.000 |
Why?
|
Platelet Aggregation | 1 | 1990 | 798 | 0.000 |
Why?
|
Neoplasm Transplantation | 1 | 1991 | 2085 | 0.000 |
Why?
|
Drug Synergism | 1 | 1991 | 1792 | 0.000 |
Why?
|
Cognition Disorders | 1 | 2001 | 4043 | 0.000 |
Why?
|
Chromosome Mapping | 2 | 1985 | 4740 | 0.000 |
Why?
|
Chromosome Aberrations | 1 | 1992 | 1813 | 0.000 |
Why?
|
Electroencephalography | 1 | 2001 | 6150 | 0.000 |
Why?
|
Leukopenia | 1 | 1985 | 212 | 0.000 |
Why?
|
Feasibility Studies | 1 | 1995 | 5078 | 0.000 |
Why?
|
DNA, Recombinant | 1 | 1985 | 476 | 0.000 |
Why?
|
Chromosomes, Human, 1-3 | 1 | 1984 | 23 | 0.000 |
Why?
|
Chromosomes, Human, 6-12 and X | 1 | 1984 | 80 | 0.000 |
Why?
|
Receptors, Interferon | 1 | 1984 | 115 | 0.000 |
Why?
|
Lymphatic Diseases | 1 | 1985 | 324 | 0.000 |
Why?
|
Sarcoma, Kaposi | 1 | 1985 | 370 | 0.000 |
Why?
|
Burkitt Lymphoma | 1 | 1984 | 327 | 0.000 |
Why?
|
Sensitivity and Specificity | 1 | 1997 | 14722 | 0.000 |
Why?
|
Cell Survival | 1 | 1991 | 5882 | 0.000 |
Why?
|
2',5'-Oligoadenylate Synthetase | 1 | 1980 | 27 | 0.000 |
Why?
|
Simian virus 40 | 1 | 1980 | 295 | 0.000 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 1980 | 197 | 0.000 |
Why?
|
Genetic Markers | 1 | 1985 | 2634 | 0.000 |
Why?
|
RNA, Ribosomal | 1 | 1980 | 246 | 0.000 |
Why?
|
Cloning, Molecular | 1 | 1984 | 4320 | 0.000 |
Why?
|
Kinetics | 1 | 1984 | 6473 | 0.000 |
Why?
|
Brain | 1 | 2001 | 26385 | 0.000 |
Why?
|
Base Sequence | 1 | 1984 | 12797 | 0.000 |
Why?
|
Protein Biosynthesis | 1 | 1980 | 2126 | 0.000 |
Why?
|
Escherichia coli | 1 | 1984 | 4217 | 0.000 |
Why?
|
Cell Line | 1 | 1984 | 15997 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1995 | 15165 | 0.000 |
Why?
|